MD Anderson partners with Federation Bio to develop microbiome therapy
2023-02-02
免疫疗法引进/卖出微生物疗法临床研究
Preview
来源: Pharmaceutical Technology
MD Anderson and Federation Bio will design and develop a synthetic microbial consortium to treat immunotherapy-resistant cancer patients. Credit: National Cancer Institute on Unsplash.
The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.
The collaboration is aimed at designing and developing a complex, synthetic microbial consortium to expand the number of cancer patients who respond to immunotherapy.
It combines the expertise and capabilities of Platform for Innovative Microbiome and Translational Research (PRIME-TR) of MD Anderson with the ACT (anaerobic co-culture technology) platform of Federation Bio.
Under the agreement, both Federation Bio and MD Anderson will rationally design a complex bacteria consortium derived from a donor faecal sample, which showed the ability to improve immunotherapy responses in patients with cancer through FMT in a study.
Federation Bio will leverage its ACT platform for manufacturing the consortium from purified cell lines, creating a therapy that includes the complete metabolic complexity of the identified microbiome.
The platform enables highly controlled bacterial consortia production, which is designed for addressing a wide range of disorders and diseases.
Federation Bio CEO Emily Drabant Conley said: “We are proud to be collaborating with MD Anderson, an institution that is leading the charge globally to advance microbiome-based approaches that could dramatically improve outcomes for cancer patients.
“We’ve demonstrated that our ACT platform enables the manufacture of complex, rationally designed microbial consortia at scale through the manufacture of FB-001, and this collaboration enables us to explore its potential in oncology, where there is both a high unmet need and evidence supporting the critical role of the microbiome in driving therapeutic response.”
The company previously used the ACT platform for designing and manufacturing the investigational oral therapy, FB-001, which comprises 148 bacterial strains isolated from multiple healthy donors.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。